Ventric Health Resources Hub
Your destination for evidence-driven heart failure decision support.
Our resources hub is designed to help you make informed decisions with evidence organized around real-world impact. You’ll discover peer-reviewed research, clinical validation, workflow insights and economic evidence around the questions decision-makers face.
Filter by topic or content type to quickly find the information most relevant to your role, setting and priorities. For additional information about the Vivio System, browse our FAQs.
Seeking Peer-Reviewed Evidence?
Vivio’s clinical validity is established by landmark peer-reviewed studies and recognized by leading clinical media. See Vivio validated in literature >
How Vivio Brings Non-Invasive Heart Failure Detection to Primary Care
VentricHealth’s Vivio System is a rapid, FDA-cleared, non-invasive test that identifies elevated LVEDP at the point of care. The brochure positions Vivio as a way to detect heart failure earlier, improve provider decision-making, and support better patient outcomes and cost savings in primary care.
Vivio Guide Maps HF Detection and Management Pathway
This resource outlines Vivio’s five-step pathway for identifying at-risk patients, assessing symptoms and filling pressures, supporting diagnosis, and guiding GDMT-based management in primary care. It also emphasizes why resting echocardiography can miss early HF and positions the workflow as an evidence-aligned care guide.
Heart Failure: Do’s, Don’ts & Asymptomatic Screening
This webinar offers clinicians, health plans and at-risk providers a practical framework for heart failure management, contrasting evidence-based best practices with common pitfalls. Topics include identifying asymptomatic patients, preventing disease progression, and aligning care with value-based goals. Featuring real-world perspectives from primary care physicians actively using Vivio, in conversation with a Rise Health cardiologist.
JAMA Review: Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) affects millions and carries high hospitalization and mortality rates. Often driven by comorbidities like hypertension, obesity and diabetes, it can present with clear congestion or unexplained exertional dyspnea. Learn how emerging diagnostics and therapies (including SGLT2 inhibitors, lifestyle changes, and targeted management) are reshaping care.
Heart Failure and SGLT2 Inhibitors: Access Has Improved, Utilization Has Not
For years, low uptake of guideline-directed therapy in heart failure has been blamed on access barriers—formulary limits, prior authorizations, step edits and patient costs. The assumption: fix access, and use will rise. But the access landscape has evolved. Explore why closing the GDMT gap now requires a new strategy in 2026.
Distinguished Cardiologists Join Our Advisory Board
Ventric Health announced the appointment of two renowned cardiologists Javed Butler, MD, MPH, MBA and Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FESC to its Clinical Advisory Board. These strategic appointments reinforce Ventric Health’s commitment to clinical excellence as the company scales the commercial expansion of its flagship Vivio® System.
Redesigned Website to Advance Earlier Heart Failure Detection
Ventric Health's new website deepens clinical and operational content for primary care physicians, cardiologists, Medicare ACOs, and health systems working to close the heart failure diagnosis gap. Enhanced features include: expanded Resources Hub with research and workflow guidance, a streamlined demo request experience, deeper content on the Vivio System’s implementation and robust library of FAQs.
JACC Noninvasive Screening for Elevated LVEDP Study
This primary-care screening study found nearly 40% of high-risk outpatients had elevated LVEDP detected non-invasively, many without a prior heart-failure diagnosis. The results demonstrate how objective physiologic assessment can be integrated into routine workflows to uncover hidden cardiac risk and support earlier referral, monitoring, and escalation decisions.
Innovating Heart Failure: Start-Ups Harness Natural Pathways
In the March 2026 edition of MedTech Strategist, next-generation start-ups are examined for tackling heart failure as a systemic condition by harnessing natural physiological pathways. Ventric Health is featured prominently for its FDA-cleared Vivio device, which brings noninvasive early heart failure detection to primary care — identifying elevated filling pressures in both HFrEF and HFpEF patients before symptoms fully emerge.
HF prevention framework spans risk to advanced disease
This joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology reframes heart failure care as a lifelong prevention continuum. It links risk-factor control, early detection, secondary prevention, and advanced-therapy care into one roadmap for clinicians and systems.
JAHA Multicenter Validation Study (2025)
Screening patients for elevated LVEDP using a novel noninvasive brachial cuff-ECG system validated a scalable method for detecting a key physiologic marker of heart failure often missed in routine care. The study shows filling pressures can be identified accurately at the point of care, supporting earlier intervention and reducing diagnostic delay across primary and community settings.
HFSA Prevention Abstract (2025)
Presented at HFSA, this analysis shows non-invasive sensing can detect early volume overload in Stage A patients before symptoms develop. The findings support prevention-focused care models that identify physiologic risk sooner. For value-based care leaders, the evidence reinforces opportunities to intervene earlier and reduce downstream clinical deterioration and cost burden.
